<DOC>
	<DOCNO>NCT00420511</DOCNO>
	<brief_summary>Type 2 diabetes mellitus ( T2DM ) chronic metabolic disorder characterize progressive deterioration function pancreatic beta-cells , cell produce secrete insulin ( hormone primarily responsible handle glucose body ) . The investigator propose double-blind , randomize control pilot study compare effect sitagliptin ( novel anti-diabetic drug beta-cell protective potential ) versus placebo , preservation beta-cell function one year patient T2DM metformin , first-line agent treatment T2DM ( ie . study group ( ) sitagliptin metformin versus ( ii ) placebo metformin ) . This study may demonstrate important beta-cell protective capacity sitagliptin . Hypothesis : In patient T2DM metformin , treatment DPP-IV inhibitor sitagliptin preserve pancreatic beta-cell function .</brief_summary>
	<brief_title>Beta-Cell Function Sitagliptin Trial ( BEST )</brief_title>
	<detailed_description>Medications currently use treatment T2DM show modify progressive decline beta-cell function occurs time . Recent evidence , however , suggest new class anti-diabetic medication , call dipeptidyl peptidase-IV ( DPP-IV ) inhibitor , may able protect beta cell hence alter natural history T2DM . We thus wish study effect sitagliptin ( DPP-IV inhibitor ) preservation beta-cell function patient T2DM randomize either ( ) sitagliptin metformin ( ii ) placebo metformin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Men woman age 30 75 inclusive 2 . Physiciandiagnosed type 2 diabetes 02 oral hypoglycemic agent 3 . Negative antiglutamic acid decarboxylase ( antiGAD_ antibody ( rule Latent Autoimmune Diabetes Adults ( LADA ) 4 . A1c screen 6.5 % 9 % inclusive oral hypoglycemic agent 6.0 % 9.0 % inclusive 12 oral hypoglycemic agent 1 . Current insulin therapy 2 . Type 1 diabetes secondary form diabetes 3 . Any major illness life expectancy &lt; 5 year may interfere patient 's participation study 4 . Involvement study require drug therapy 5 . Renal dysfunction evidence serum creatinine &gt; /= 136 umol/L male &gt; /= 124 umol/L female abnormal creatinine clearance ( &lt; 60 ml/min Modification Diet Renal Disease ( MDRD ) formula ) 6 . Hepatic disease consider clinically significant ( include jaundice , chronic hepatitis , previous liver transplant ) transaminases &gt; 2.5 time upper limit normal 7 . Excessive alcohol consumption , define &gt; 14 alcoholic drink per week male &gt; 9 alcoholic drink per week female 8 . Pregnancy unwillingness use reliable contraception . Women plan pregnancy duration study . Reliable contraception include : birth control pill , intrauterine device , abstinence , tubal ligation , partner vasectomy , condom spermicide . Any woman miss menstrual period think may pregnant must pregnancy test soon possible 9 . History serious arrhythmia atrioventricular block baseline electrocardiogram 10 . Uncontrolled hypertension ( systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 110 mm Hg ) 11 . Unwillingness undergo multiple daily insulin injection therapy 4 week 12 . Unwillingness perform capillary blood glucose monitoring least 4 time per day intensive insulin therapy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>beta-cell function</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>intensive insulin therapy</keyword>
</DOC>